{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T01:14:47Z","timestamp":1795137287444,"version":"4.10.3"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T00:00:00Z","timestamp":1587686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T00:00:00Z","timestamp":1587686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Small molecules that selectively kill senescent cells (SCs), termed senolytics, have the potential to prevent and treat various age-related diseases and extend healthspan. The use of Bcl-xl inhibitors as senolytics is largely limited by their on-target and dose-limiting platelet toxicity. Here, we report the use of proteolysis-targeting chimera (PROTAC) technology to reduce the platelet toxicity of navitoclax (also known as ABT263), a Bcl-2 and Bcl-xl dual inhibitor, by converting it into PZ15227 (PZ), a Bcl-xl PROTAC, which targets Bcl-xl to the cereblon (CRBN) E3 ligase for degradation. Compared to ABT263, PZ is less toxic to platelets, but equally or slightly more potent against SCs because CRBN is poorly expressed in platelets. PZ effectively clears SCs and rejuvenates tissue stem and progenitor cells in naturally aged mice without causing severe thrombocytopenia. With further improvement, Bcl-xl PROTACs have the potential to become safer and more potent senolytic agents than Bcl-xl inhibitors.<\/jats:p>","DOI":"10.1038\/s41467-020-15838-0","type":"journal-article","created":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T06:27:15Z","timestamp":1587709635000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":249,"title":["Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4409-4590","authenticated-orcid":false,"given":"Yonghan","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6062-6708","authenticated-orcid":false,"given":"Xuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhui","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2498-6700","authenticated-orcid":false,"given":"Ha-Neui","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1331-8846","authenticated-orcid":false,"given":"Sajid","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4677-8996","authenticated-orcid":false,"given":"Dongwen","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Thummuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxia","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet S.","family":"Wiegand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuma T.","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivekananda","family":"Budamagunta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer H.","family":"Elisseeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Campisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8106-6663","authenticated-orcid":false,"given":"Guangrong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2400-6461","authenticated-orcid":false,"given":"Daohong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,24]]},"reference":[{"key":"15838_CR1","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/nm.4000","volume":"21","author":"BG Childs","year":"2015","unstructured":"Childs, B. G., Durik, M., Baker, D. J. & van Deursen, J. M. Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat. Med. 21, 1424\u20131435 (2015).","journal-title":"Nat. Med."},{"key":"15838_CR2","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/nrd.2017.116","volume":"16","author":"BG Childs","year":"2017","unstructured":"Childs, B. G. et al. Senescent cells: an emerging target for diseases of ageing. Nat. Rev. Drug Discov. 16, 718\u2013735 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"15838_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ebiom.2017.04.013","volume":"21","author":"JL Kirkland","year":"2017","unstructured":"Kirkland, J. L. & Tchkonia, T. Cellular senescence: a translational perspective. EBioMedicine 21, 21\u201328 (2017).","journal-title":"EBioMedicine"},{"key":"15838_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/nrd.2018.44","volume":"17","author":"LJ Niedernhofer","year":"2018","unstructured":"Niedernhofer, L. J. & Robbins, P. D. Senotherapeutics for healthy ageing. Nat. Rev. Drug Discov. 17, 377 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"15838_CR5","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1172\/JCI95149","volume":"128","author":"Y Ovadya","year":"2018","unstructured":"Ovadya, Y. & Krizhanovsky, V. Strategies targeting cellular senescence. J. Clin. Invest. 128, 1247\u20131254 (2018).","journal-title":"J. Clin. Invest"},{"key":"15838_CR6","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nrm3823","volume":"15","author":"D Mu\u00f1oz-Esp\u00edn","year":"2014","unstructured":"Mu\u00f1oz-Esp\u00edn, D. & Serrano, M. Cellular senescence: from physiology to pathology. Nat. Rev. Mol. Cell Biol. 15, 482\u2013496 (2014).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"15838_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1083\/jcb.201708092","volume":"217","author":"D McHugh","year":"2018","unstructured":"McHugh, D. & Gil, J. Senescence and aging: causes, consequences, and therapeutic avenues. J. Cell Biol. 217, 65\u201377 (2018).","journal-title":"J. Cell Biol."},{"key":"15838_CR8","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/acel.12344","volume":"14","author":"Y Zhu","year":"2015","unstructured":"Zhu, Y. et al. The Achilles\u2019 heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 14, 644\u2013658 (2015).","journal-title":"Aging Cell"},{"key":"15838_CR9","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.ebiom.2018.12.052","volume":"40","author":"N Justice","year":"2019","unstructured":"Justice, J. N. et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine 40, 554\u2013563 (2019).","journal-title":"EBioMedicine"},{"key":"15838_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ebiom.2018.09.015","volume":"36","author":"MJ Yousefzadeh","year":"2018","unstructured":"Yousefzadeh, M. J. et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine 36, 18\u201328 (2018).","journal-title":"EBioMedicine"},{"key":"15838_CR11","doi-asserted-by":"publisher","first-page":"955","DOI":"10.18632\/aging.101202","volume":"9","author":"Y Zhu","year":"2017","unstructured":"Zhu, Y. et al. New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. Aging 9, 955\u2013963 (2017).","journal-title":"Aging"},{"key":"15838_CR12","doi-asserted-by":"publisher","first-page":"e12780","DOI":"10.1111\/acel.12780","volume":"17","author":"X Zhang","year":"2018","unstructured":"Zhang, X. et al. Oxidation resistance 1 is a novel senolytic target. Aging Cell 17, e12780 (2018).","journal-title":"Aging Cell"},{"key":"15838_CR13","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.18632\/aging.101100","volume":"8","author":"Y Wang","year":"2016","unstructured":"Wang, Y. et al. Discovery of piperlongumine as a potential novel lead for the development of senolytic agents. Aging 8, 2915\u20132926 (2016).","journal-title":"Aging"},{"key":"15838_CR14","doi-asserted-by":"publisher","first-page":"771","DOI":"10.18632\/aging.101787","volume":"11","author":"W Li","year":"2019","unstructured":"Li, W., He, Y., Zhang, R., Zheng, G. & Zhou, D. The curcumin analog EF24 is a novel senolytic agent. Aging 11, 771\u2013782 (2019).","journal-title":"Aging"},{"key":"15838_CR15","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/s41591-018-0092-9","volume":"24","author":"M Xu","year":"2018","unstructured":"Xu, M. et al. Senolytics improve physical function and increase lifespan in old age. Nat. Med. 24, 1246\u20131256 (2018).","journal-title":"Nat. Med."},{"key":"15838_CR16","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nm.4010","volume":"22","author":"J Chang","year":"2016","unstructured":"Chang, J. et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat. Med. 22, 78\u201383 (2016).","journal-title":"Nat. Med."},{"key":"15838_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11190","volume":"7","author":"R Yosef","year":"2016","unstructured":"Yosef, R. et al. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat. Commun. 7, 11190 (2016).","journal-title":"Nat. Commun."},{"key":"15838_CR18","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/acel.12445","volume":"15","author":"Y Zhu","year":"2016","unstructured":"Zhu, Y. et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell 15, 428\u2013435 (2016).","journal-title":"Aging Cell"},{"key":"15838_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00314-z","volume":"8","author":"H Fuhrmann-Stroissnigg","year":"2017","unstructured":"Fuhrmann-Stroissnigg, H. et al. Identification of HSP90 inhibitors as a novel class of senolytics. Nat. Commun. 8, 422 (2017).","journal-title":"Nat. Commun."},{"key":"15838_CR20","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/nm.4324","volume":"23","author":"OH Jeon","year":"2017","unstructured":"Jeon, O. H. et al. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nat. Med. 23, 775\u2013781 (2017).","journal-title":"Nat. Med."},{"key":"15838_CR21","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.cell.2017.02.031","volume":"169","author":"MP Baar","year":"2017","unstructured":"Baar, M. P. et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell 169, 132\u2013147.e16 (2017).","journal-title":"Cell"},{"key":"15838_CR22","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz-Esp\u00edn, D. et al. A versatile drug delivery system targeting senescent cells. EMBO Mol. Med. 10, (2018).","DOI":"10.15252\/emmm.201809355"},{"key":"15838_CR23","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse, C. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421\u20133428 (2008).","journal-title":"Cancer Res."},{"key":"15838_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrd.2016.253","volume":"16","author":"A Ashkenazi","year":"2017","unstructured":"Ashkenazi, A., Fairbrother, W. J., Leverson, J. D. & Souers, A. J. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat. Rev. Drug Discov. 16, 273\u2013284 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"15838_CR25","doi-asserted-by":"publisher","first-page":"279ra40","DOI":"10.1126\/scitranslmed.aaa4642","volume":"7","author":"JD Leverson","year":"2015","unstructured":"Leverson, J. D. et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci. Transl. Med. 7, 279ra40 (2015).","journal-title":"Sci. Transl. Med."},{"key":"15838_CR26","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1200\/JCO.2010.31.6208","volume":"29","author":"L Gandhi","year":"2011","unstructured":"Gandhi, L. et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J. Clin. Oncol. 29, 909\u2013916 (2011).","journal-title":"J. Clin. Oncol."},{"key":"15838_CR27","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202\u2013208 (2013).","journal-title":"Nat. Med."},{"key":"15838_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.97","volume":"6","author":"MA Debrincat","year":"2015","unstructured":"Debrincat, M. A. et al. BCL-2 is dispensable for thrombopoiesis and platelet survival. Cell Death Dis. 6, e1721 (2015).","journal-title":"Cell Death Dis."},{"key":"15838_CR29","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/anie.201507978","volume":"55","author":"M Toure","year":"2016","unstructured":"Toure, M. & Crews, C. M. Small-Molecule PROTACS: new approaches to protein degradation. Angew. Chem. Int. Ed. Engl. 55, 1966\u20131973 (2016).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"15838_CR30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrd.2016.211","volume":"16","author":"AC Lai","year":"2017","unstructured":"Lai, A. C. & Crews, C. M. Induced protein degradation: an emerging drug discovery paradigm. Nat. Rev. Drug Discov. 16, 101\u2013114 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"15838_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.pharmthera.2019.03.003","volume":"199","author":"G Veggiani","year":"2019","unstructured":"Veggiani, G., Gerpe, M. C. R., Sidhu, S. S. & Zhang, W. Emerging drug development technologies targeting ubiquitination for cancer therapeutics. Pharmacol. Ther. 199, 139\u2013154 (2019).","journal-title":"Pharmacol. Ther."},{"key":"15838_CR32","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.pharmthera.2017.02.027","volume":"174","author":"TK Neklesa","year":"2017","unstructured":"Neklesa, T. K., Winkler, J. D. & Crews, C. M. Targeted protein degradation by PROTACs. Pharmacol. Ther. 174, 138\u2013144 (2017).","journal-title":"Pharmacol. Ther."},{"key":"15838_CR33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","volume":"31","author":"M Pettersson","year":"2019","unstructured":"Pettersson, M. & Crews, C. M. PROteolysis TArgeting Chimeras (PROTACs)\u2014past, present and future. Drug Discov. Today Technol. 31, 15\u201327 (2019).","journal-title":"Drug Discov. Today Technol."},{"key":"15838_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-14-1","volume":"14","author":"PF Bray","year":"2013","unstructured":"Bray, P. F. et al. The complex transcriptional landscape of the anucleate human platelet. BMC Genomics 14, 1 (2013).","journal-title":"BMC Genomics"},{"key":"15838_CR35","doi-asserted-by":"publisher","first-page":"e81809","DOI":"10.1371\/journal.pone.0081809","volume":"8","author":"A Kissopoulou","year":"2013","unstructured":"Kissopoulou, A., Jonasson, J., Lindahl, T. L. & Osman, A. Next generation sequencing analysis of human platelet PolyA+ mRNAs and rRNA-depleted total RNA. PLoS ONE 8, e81809 (2013).","journal-title":"PLoS ONE"},{"key":"15838_CR36","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.molcel.2016.02.032","volume":"61","author":"TV Nguyen","year":"2016","unstructured":"Nguyen, T. V. et al. Glutamine triggers acetylation-dependent degradation of glutamine synthetase via the thalidomide receptor cereblon. Mol. Cell 61, 809\u2013820 (2016).","journal-title":"Mol. Cell"},{"key":"15838_CR37","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1073\/pnas.1700949114","volume":"114","author":"TV Nguyen","year":"2017","unstructured":"Nguyen, T. V. et al. p97\/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates. Proc. Natl Acad. Sci. USA 114, 3565\u20133571 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"15838_CR38","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kr\u00f6nke","year":"2014","unstructured":"Kr\u00f6nke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301\u2013305 (2014).","journal-title":"Science"},{"key":"15838_CR39","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","volume":"22","author":"J Lu","year":"2015","unstructured":"Lu, J. et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem. Biol. 22, 755\u2013763 (2015).","journal-title":"Chem. Biol."},{"key":"15838_CR40","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.tcb.2018.02.001","volume":"28","author":"A Hernandez-Segura","year":"2018","unstructured":"Hernandez-Segura, A., Nehme, J. & Demaria, M. Hallmarks of cellular senescence. Trends Cell Biol. 28, 436\u2013453 (2018).","journal-title":"Trends Cell Biol."},{"key":"15838_CR41","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","volume":"5","author":"J-P Copp\u00e9","year":"2010","unstructured":"Copp\u00e9, J.-P., Desprez, P.-Y., Krtolica, A. & Campisi, J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 5, 99\u2013118 (2010).","journal-title":"Annu. Rev. Pathol."},{"key":"15838_CR42","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/acel.12597","volume":"16","author":"H-N Kim","year":"2017","unstructured":"Kim, H.-N. et al. DNA damage and senescence in osteoprogenitors expressing Osx1 may cause their decrease with age. Aging Cell 16, 693\u2013703 (2017).","journal-title":"Aging Cell"},{"key":"15838_CR43","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/nm.4385","volume":"23","author":"JN Farr","year":"2017","unstructured":"Farr, J. N. et al. Targeting cellular senescence prevents age-related bone loss in mice. Nat. Med. 23, 1072\u20131079 (2017).","journal-title":"Nat. Med"},{"key":"15838_CR44","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1021\/acschembio.5b00216","volume":"10","author":"M Zengerle","year":"2015","unstructured":"Zengerle, M., Chan, K.-H. & Ciulli, A. Selective small molecule induced degradation of the BET bromodomain protein BRD4. ACS Chem. Biol. 10, 1770\u20131777 (2015).","journal-title":"ACS Chem. Biol."},{"key":"15838_CR45","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","volume":"25","author":"DP Bondeson","year":"2018","unstructured":"Bondeson, D. P. et al. Lessons in PROTAC design from selective degradation with a promiscuous warhead. Cell Chem. Biol. 25, 78\u201387.e5 (2018).","journal-title":"Cell Chem. Biol."},{"key":"15838_CR46","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.bbamcr.2003.08.012","volume":"1644","author":"AM Petros","year":"2004","unstructured":"Petros, A. M., Olejniczak, E. T. & Fesik, S. W. Structural biology of the Bcl-2 family of proteins. Biochim. Biophys. Acta 1644, 83\u201394 (2004).","journal-title":"Biochim. Biophys. Acta"},{"key":"15838_CR47","doi-asserted-by":"publisher","first-page":"e1006868","DOI":"10.1371\/journal.ppat.1006868","volume":"14","author":"D-W Lv","year":"2018","unstructured":"Lv, D.-W., Zhang, K. & Li, R. Interferon regulatory factor 8 regulates caspase-1 expression to facilitate Epstein-Barr virus reactivation in response to B cell receptor stimulation and chemical induction. PLoS Pathog. 14, e1006868 (2018).","journal-title":"PLoS Pathog."},{"key":"15838_CR48","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402\u2013408 (2001).","journal-title":"Methods"},{"key":"15838_CR49","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.devcel.2014.11.012","volume":"31","author":"M Demaria","year":"2014","unstructured":"Demaria, M. et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev. Cell 31, 722\u2013733 (2014).","journal-title":"Dev. Cell"},{"key":"15838_CR50","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1182\/blood-2013-07-515619","volume":"123","author":"L Shao","year":"2014","unstructured":"Shao, L. et al. Total body irradiation causes long-term mouse BM injury via induction of HSC premature senescence in an Ink4a- and Arf-independent manner. Blood 123, 3105\u20133115 (2014).","journal-title":"Blood"},{"key":"15838_CR51","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1038\/nprot.2009.191","volume":"4","author":"F Debacq-Chainiaux","year":"2009","unstructured":"Debacq-Chainiaux, F., Erusalimsky, J. D., Campisi, J. & Toussaint, O. Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat. Protoc. 4, 1798\u20131806 (2009).","journal-title":"Nat. Protoc."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-15838-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-15838-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-15838-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T15:59:07Z","timestamp":1670255947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-15838-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,24]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["15838"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-15838-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,24]]},"assertion":[{"value":"14 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"X.Z., J.C., Y.W., G.Z., and D.Z. are inventors of a pending patent application for use of Bcl-xl PROTACs as senolytic agents. J.C. and D.Z. are co-founders and stockholders of Unity Biotechnology that develops senolytics to treat age-related diseases. J.H.E. is an advisor and stockholder of Unity Biotechnology. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1996"}}